Distribution Agreement with Byoplanet for High End Electrostatic Sprayers, Expanding Capability to Treat Any Size Facility

WEST PALM BEACH, FL / ACCESSWIRE / July 27, 2015 / FastFunds Financial Corporation (OTCPK: FFFC) (the Company or FastFunds) announced today that Pure Grow Systems, LLC, a subsidiary of FastFunds Financial Corporation, has signed a distribution agreement with Byoplanet to market its high end electrostatic sprayers, giving Pure Grow the capability to treat any size facility. The Byoplanet ES120 sprayer is the worlds most advanced chemical delivery system. It utilizes induction charged technology to produce electrically charged droplets that reach further and penetrate deeper, allowing 100% of the surface to be reached; including hidden areas and sensitive equipment.

We are excited to be adding this state of the art product line to complement our antimicrobial sanitation system for grow facilities, said Russ Mitchell, Pure Grow Systems managing partner. The capability to reach 100% of the surfaces being treated including hidden areas and sensitive equipment will give our customers the ultimate value.

Based on the recent label approval in Nevada, Pure Grow will commence their advertising campaign shortly. The Company is expecting additional label approvals in the near future and the shareholders will be updated as these events occur.

About FastFunds Financial Corporation

FastFunds Financial Corporation (“FastFunds” or the “Company”) is a holding company that is publicly traded on the OTC Pink exchange, under the symbol “FFFC.” Through its wholly-owned subsidiaries, Cannabis Angel, Inc. and The 420 Development Corporation, the Company is focused on acquiring and building a portfolio of revenue producing companies that provide ancillary services to the cannabis industry. FastFunds does not engage in activities that violate Federal laws.

Safe Harbor for Forward-looking Statements

This news release may contain forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. While these statements are made to convey to the public the companys progress, business opportunities and growth prospects, they are based on managements current beliefs and assumptions as to future events. However, since the companys operations and business prospects are always subject to risk and uncertainties, the forward-looking events and circumstances discussed in this news release might not occur, and actual results could differ materially from those described, anticipated or implied. For a more complete discussion of such risks and uncertainties, please refer to the company’s filings with the Securities and Exchange Commission.

CONTACTS:

FastFunds Financial Corporation
Henry Fong, CEO
561-514-9042

SOURCE: FastFunds Financial Corporation

ReleaseID: 430828

SEATTLE, WA / ACCESSWIRE / July 27, 2015 / CannabisFN (“CFN”), a dedicated agency and media network for companies, entrepreneurs and brands operating in the burgeoning multi-billion dollar legal marijuana industry, today announced the release of video interviews filmed at the Cannabis World Congress & Business Expo (CWCBExpo) on June 18th at the Jacob K. Javits Convention Center in New York City, New York.

The 2nd Annual CWCBExpo, a premier event connecting industry professionals and investors, attracted thousands of attendees from the U.S. and around the world seeking to build their businesses, raise capital, and learn of investment opportunities.

As one of the CWCBExpo’s official media partners, CFN captured live interviews from the expo floor of exhibiting companies, speakers, and thought leaders. The public can access the video footage on CFN at http://www.cannabisfn.com/ and http://www.cannabisfn.com/video-library/?vchannel=Cannabis-World-Congress-Business-Exposition-Interview-Series&vorder=date:desc.

The expo was a seminal event for the legal marijuana industry that convened key leadership in the areas of capital formation, innovation and business development,” said Frank Lane, President of CFN.

CFN would like to thank all participants for making the CWCBExpo an incredible success and we look forward to providing investors and entrepreneurs more post event coverage very soon.

Those interested in attending the next CWCBExpo in Los Angeles, CA on September 16th – 18th can inquire and register here:
http://www.cwcbexpo.com/los-angeles-show/

Learn how to become a featured company, brand or entrepreneur:
http://www.cannabisfn.com/become-featured-company/

To subscribe to the CFN weekly newsletter or read additional coverage on cannabis laws and investments, visit: http://www.cannabisfn.com/capitalize-on-cannabis/

About CFN

Cannabis Financial Network (CannabisFN or CFN) is brought to you by TDM Financial, a financial media group and owner of SECFilings.com with over a decade of experience educating the markets, profiling public and private companies, and developing specific investor audiences. CFN is the largest dedicated financial network covering the legal marijuana industry and publishes industry news, thought leader and executive interviews, and stories on the fluid business and regulatory environment while serving as a leading corporate communications platform for marijuana companies, entrepreneurs and brands.

Frank Lane
President
CFN
(206) 369-7050
flane@cannabisfn.com

SOURCE: Cannabis Financial Network

ReleaseID: 430849

SEATTLE, WA / ACCESSWIRE / July 27, 2015 / The cannabis industry could be worth $35 billion by 2020, according to GreenWave Advisors, and the majority of the revenue is likely coming from early adopters. As existing users of cannabis and cannabinoid extracts, they already know the difference between tetrahydrocannabinol (“THC”), cannabidiol (“CBD”), and other cannabinoids, as well as the difference between various strains of marijuana, such as Charlotte’s Web.

Surprisingly, many companies don’t seem quite as knowledgeable as their customers when it comes to selling cannabis products. The U.S. FDA released a report in February 2015 warning manufacturers of CBD products to scale back on their marketing, while noting that many products didn’t even contain any CBDs, despite their claims. In fact, nearly half of the products tested were negative for cannabinoids and many had only small concentrations!

Lexaria Corp. (OTCQB: LXRP), a Canada-based developer of hemp oil infused health and wellness products, has developed an infusion technology that increases the bioavailability of CBDs to potentially enhance the effects on the human body. In this article, we’ll take a closer look at this approach and why the company’s growing portfolio of products – including CBD-infused teas – aren’t your average CBD-infused products.

Lack of Accountability

The FDA’s scathing report warning CBD manufacturers highlighted the fact that many companies aren’t including very much CBD in their products. (None of the products tested were from Lexaria Corp.)

A product called UltraCBD tested negative for any cannabinoids in one sample and tested for just 0.02% in another, according to the FDA, despite a name suggesting a high concentration of the substance. On its website, the company boasts that the product is “made in a cGMP lab environment to the highest standards and is thoroughly tested and sealed with a high quality glass dropper for exact dosing, the expiration date, and lot # stamped on each bottle.”

Many customers are purchasing hemp oil for the CBD content, since the substance has been linked to a number of potential health benefits. Despite the promises being made by many manufacturers, there’s no process in place to ensure accountability when it comes to the actual concentrations that appear in the products. Customers who believe they’re consuming CBDs may in fact be consuming an oil that doesn’t contain any beneficial compounds.

Importance of Bioavailability

The second key problem with CBDs is the bioavailability to the human body, which varies tremendously between individuals.

According to a NIH study, orally consumed marijuana delivers THC at an average bioavailability rate of just 5% compared to an average rate of 30% when smoking the substance. The same problem is likely occurring with CBDs – which share many characteristics with THCs as a fellow cannabinoid compound. For consumers, this means that orally consumed hemp oil may not be absorbed by the body in any meaningful way, especially when the amounts are low.

Lexaria’s proprietary lipid-infusion technology platform combats these issues by encapsulating CBD compounds in a lipid molecule that’s more readily absorbed into the body. While specific studies are still underway, management has indicated that early results have shown tremendous promise in increasing the absorption (and thereby effectiveness) of CBDs, which means that more effects can be observed with smaller concentrations.

Compelling Value

Lexaria’s ViPova teas represent its initial foray into the CBD-infused food and beverage industry, leveraging its proprietary lipid-infusion technology platform.

Many CBD-infused products sell for a premium given the high price associated with extracting CBDs from hemp oil. For instance, many CBD oils listed for sale on Google Shopping are priced at upwards of $50 to $75 per ounce in dropper form and have notoriously bad aftertastes. ViPova is formulated in a great-tasting tea targeted to contain ~10mg of CBD for just $3.00 per serving, with a greater effectiveness relative to competitors that don’t have the infusion technology.

Natural/Organic food sales reached $81.3 billion in 2012, up 13.5% from the year before, according to the Organic Trade Association. This compelling evidence of the demand for healthy foods holds one of the keys to Lexaria’s strategy of combining hemp-derived CBD into other healthy food choices in pursuit of the next superfood craze.

Moving forward, the company is preparing for the imminent launch of a number of other hemp oil infused products across additional food categories, including mostly organic protein energy bars. Customers can purchase the products on the company’s website, www.vipova.com, or through a growing network of physical and online retailers that are carrying the product. The company has also established an affiliate program designed to help support peer-to-peer sales.

Looking Ahead

Lexaria is uniquely positioned within the cannabis industry as a provider of enhanced CBD-infused products. In contrast to other companies in the space, such as Medical Marijuana Inc.’s (OTCQB: MJNA) focus on cannabinoid research, CannLabs Inc.’s (OTCQB: CANL) focus on testing, or MedBox Inc.’s (OTCQB: MDBX) focus on providing consulting services to the marijuana industry, the company has existing products on the market that are targeting consumers looking for high quality CBD sources.

For more information, visit the company’s website at www.lexariaenergy.com.

Legal Disclaimer:

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.

SOURCE: Emerging Growth LLC

ReleaseID: 430848

Kahala Aviation Announces Upcoming Acquisition by Diamond Head Aviation 2015 Limited of 30 Aircraft Portfolio And Related Note Offering

DUBLIN, IRELAND / ACCESSWIRE / July 27, 2015 / Kahala Aviation Holdings LLC (“Kahala”) announces the upcoming acquisition of an aircraft portfolio comprised of both narrow-body and wide-body aircraft by Diamond Head Aviation 2015 Limited from AWAS Aviation Capital Limited. The acquisition will be financed by US$199,250,000 of 3.81% Class A Fixed Rate Asset Backed Notes and US$61,500,000 of 5.92% Class B Fixed Rate Asset Backed Notes (together, the “Notes”) and also the issuance of Class E Notes to Kahala Ireland Investments Designated Activity Company, an affiliate of Kahala. The transaction is expected to close on or about July 30, 2015.

Important Notice Regarding the Issue:

The Notes will be offered only to qualified institutional buyers under Rule 144A and to persons outside the United States under Regulation S. The Notes will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act”), and, unless so registered, may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. The Notes will only be offered in conformity with Irish national law and with Directive 2003/71/EC as amended and implemented into relevant national laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the Notes in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state. This press release shall not constitute an offer of the Notes to the public in any member state of the European Economic Area.

About Kahala Aviation Holdings LLC:

Kahala Aviation Ltd. is a global aviation company engaged in acquiring, leasing and trading used commercial aircraft.

Our focus is ten year or older narrow-body aircraft, regional jets and large turboprops. In addition we are one of the leading lessors of 737 freighter aircraft in the world. We also offer structured finance solutions and aircraft management services for our industry clients.

Our founders are Bradley Smith, Michael Garland, Mark Thatcher and Michael Howard all of whom have substantial experience in the aviation and aircraft leasing sectors. Our management team has, in the main, worked together for 10 years during which time we have successfully acquired over 80 aircraft with an aggregate purchase price of approximately $600 million in addition to trading aircraft mortgage securities and loans.

For more information on Kahala Aviation see: www.kahalaaviation.com

Media Contact:
Bradley E Smith
+1-808-375-0138
bsmith@kahalacapital.com
www.kahalaaviation.com

SOURCE: Kahala Aviation Holdings LLC

ReleaseID: 430834

NEW YORK, NY / ACCESSWIRE / July 27, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on General Employment Enterprises, Inc. (NYSE MKT: JOB).

“In line with the strategy that has been articulated by management since we initiated coverage on the company last September, General Employment announced it would issue 11.2mn shares of new equity pursuant to the $75mn shelf offering filed with the SEC, with proceeds intended to fund growth through acquisitions and for general corporate purposes. On July 23, 2015, the company priced the offering at $0.70 per share, in a transaction that was led by Roth Capital and co-managed by Maxim Group,” commented Ajay Tandon, CEO of SeeThruEquity. “We have been impressed by the considerable progress made by General Employment under the leadership of Derek Dewan and Andrew Nostrud since we initiated coverage last Autumn. In our view the company has executed a remarkable turnaround, and we see General Employment as evolving from a deep value special situation to a growth company taking share in a large and fragmented industry. We are maintaining a price target of $2.00 following the company’s recent equity raise.”

The report is available here: JOB July 2015 Update Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

Additional highlights from the update note are as follows:

New equity bolsters financial strength

On July 22, 2015, General Employment announced that it had priced an 11.2mn share offering of common stock at $0.70 per share, with the proceeds earmarked for new acquisitions and general corporate purposes. The shares were offered pursuant to a $75mn shelf registration filed with the SEC in May and highlighted in our June note on JOB. We estimate General Employment will receive approximately $7.3mn in proceeds after expenses and underwriting discounts, with potential for an additional $1.1mn if underwriters exercise their 30-day overallotment option in full. The move is the latest in a series of transactions that have strengthened the company’s balance sheet, including completion of a debt to equity conversion by Brio Master Fund in May 2015 and also the conversion of all the preferred shares to common as of the close of the offering.

Balance sheet to be clean for first time in our coverage

Adjusting March quarter results for the $7.3mn in net proceeds we form the offering, General Employment has a much-improved balance sheet. We estimate the company to have an adjusted cash balance of approximately $8.4mn in cash on hand and a current ratio of over 2.0x, with 86.5mn common shares outstanding. Importantly, the company should move to a net cash position of positive $1.7mn on the balance sheet and shareholder’s equity of $18.6mn with a book value of $0.22 per share. This is remarkable progress for a company that was in continuing default on a short-term credit facility when we initiated coverage last September. We also note that JOB shares have appreciated by over 300% since our initiation due to the considerable progress made by the company since that time.

Proceeds likely to include funds for an acquisition

We see the raise as what is likely the beginning of a new growth phase for General Employment. After integrating the acquisition of Scribe Solutions – recently named one of the fifty fastest growing private companies in North Florida – we expect new CEO Derek Dewan and CFO Andrew Nostrud to deploy a substantial portion of the proceeds for accretive acquisitions. Acquisitions are likely to be a core supplement to organic growth in the company’s strategy going forward, given the manifold opportunities in the highly fragmented $139Bn staffing and executive search industry.

Please review important disclosures on our website at www.seethruequity.com.

About General Employment Enterprises, Inc.

General Employment Enterprises, Inc. was incorporated in the State of Illinois in 1962, is a provider of specialized staffing solutions and is the successor to employment offices doing business since 1893. The Company operates in two industry segments, providing professional staffing services and solutions, and light industrial staffing services through the names of General Employment, Ashley Ellis, Triad and Omni-One. Also, in the healthcare sector, General Employment through its Scribe Solutions brand staffs medical scribes who assist physicians in emergency departments of hospitals and in medical practices by providing required documentation for patient care in connection with electronic medical records (EMR).

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 430842

NEW YORK, NY / ACCESSWIRE / July 27, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of Great Basin Scientific Inc. (NASDAQ: GBSN) with a 12 month price target of $9.38.

The report is available here: GBSN Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

GBSN is a molecular diagnostics testing company that develops, manufactures and commercializes its molecular diagnostic platforms for affordable and reliable infectious disease tests, mainly for small to medium sized hospitals. The Company sells its diagnostic tests through a direct sales force in the United States, as well as through distributors in the European Union and New Zealand. Great Basin Scientific Inc. is headquartered in Salt Lake City, Utah. In April 2015, GBSN received FDA clearance for Group B Strep molecular diagnostic assay. Group B Strep was GBSN’s second assay approved by FDA after the C. diff test was approved in May 2012. GBSN has additional assays in clinical trials and assays under development. GBSN holds trade secrets, copyrights, contractual provisions and technical measures to sustain and improve its competitive position with regards to intellectual property.

“We are intrigued by Great Basin’s focus on small-and-medium sized hospitals, as the company believes it’s a fast-growing market due to an increasing number of hospitals replacing their less accurate testing formats to more accurate molecular diagnostic testing. Its cost-effective platform is well positioned to satisfy the medical needs from these hospitals,” commented Ajay Tandon, CEO of SeeThruEquity. “We are initiating coverage with a 12-month price target of $9.38 per share.”

Additional highlights from the report are as follows:

GBSN’s Clear Market Focus on Small-and-Medium Sized Hospitals

In 2012, around 86% (4,900 out of 5,700) of all hospitals in the United States were under 400 beds, which are known as small-and-medium sized hospitals. The total number of small-and-medium sized hospitals is growing significantly every year. Additionally, fewer than half of those smaller hospitals have made the switch to molecular methods for diagnosing infectious disease for its high accuracy, easy-to-use, and speedy characteristics. GBSN is leveraging its low-cost platform to quickly penetrate a variety of health care companies, with a focus on the small-and-medium sized hospitals. The affordable molecular diagnostic testing systems help these hospitals to improve their testing accuracy and to offer their patients more affordable service, as well. GBSN is growing its sales force domestically and internationally to meet the larger demand. GBSN expects the increasing number of customers will consume more diagnostic cartridges it designs and bring more revenue to the company in the foreseeable future.

Expand Menu of Molecular Diagnostic Assays to Grow Revenue

To meet the growing medical needs, GBSN will expand its assay menu to include the five additional assays currently under development, bringing more commercial opportunities to the Company. GBSN estimates the total domestic market opportunity is about $1.3 to $1.6 billion. Specifically, for the available C. diff test, the entire annual market revenue is roughly $110 to $120 million. For Group B Strep that was recently approved, the overall potential market is $80 to $120 million annually. Group B has just commercially launched and various hospitals and laboratories are evaluating this diagnostic for use, while two US laboratories have already adopted this accurate and cost saving strep test. Staphylococcus Blood Infection Pane that is under development accounts for a total market of $100 to $150 million annually, Staphylococcus Aureus Pre-Surgical Screening is estimated at $800 to $900 million annually, and Food Borne Pathogens Panel is expected to generate $150 to $200 million annually.

Automation and Volume Purchasing to Reduce Cost of Sales

GBSN manufactures its proprietary diagnostic cartridges and analyzers at its headquarters in Salt Lake City. The Company currently hand-builds its diagnostic cartridges and purchase materials at higher per unit cost due to lower purchase volumes. GBSN is investing in automating portions of the manufacturing and assembly process and volume purchase pricing.

Initiate coverage with a price target of $9.38

Our analysis indicates a fair value estimate of $9.38 per share, implying an upside of 281.3% from the recent price of $2.46.

Please review important disclosures on our website at www.seethruequity.com.

About Great Basin Scientific Inc.

Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease.

For more information on the Company, its products and services, please visit www.gbscience.com.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 430845